<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-09-23T20:01:29Z</responseDate><request verb="GetRecord" identifier="oai:repository.ajou.ac.kr:201003/11887" metadataPrefix="oai_dc">https://repository.ajou.ac.kr/oai/request</request><GetRecord><record><header><identifier>oai:repository.ajou.ac.kr:201003/11887</identifier><datestamp>2024-10-11T02:21:24Z</datestamp><setSpec>com_201003_14369</setSpec><setSpec>com_201003_14368</setSpec><setSpec>col_201003_14371</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
<dc:title>TLR4 endogenous ligand S100A8/A9 levels in adult-onset Still’s disease and their association with disease activity and clinical manifestations</dc:title>
<dc:title>성인형스틸씨병에서 TLR4 내인리간드 S1008/A9의 질병활성화 표지자로서 역할 및 임상 양상과의 관련성</dc:title>
<dc:creator>김, 현아</dc:creator>
<dc:contributor>서, 창희</dc:contributor>
<dc:contributor>대학원 의학과</dc:contributor>
<dc:contributor>104569</dc:contributor>
<dc:contributor>김, 현아</dc:contributor>
<dc:subject>Adult-onset Still's disease</dc:subject>
<dc:subject>S100A8/A9</dc:subject>
<dc:subject>disease activity</dc:subject>
<dc:subject>biomarker</dc:subject>
<dc:subject>interleukin-1β</dc:subject>
<dc:description>Objective: S100A8/A9 has been suggested as a biomarker of disease activity in patients with systemic juvenile idiopathic arthritis or adult-onset Still’s disease (AOSD). We investigated the clinical significance and the pathogenic role of this marker in AOSD. 



Materials and Methods: Serum samples were collected from 36 AOSD patients, 40 rheumatoid arthritis (RA) patients, and 33 healthy controls (HC) for enzyme-linked immunosorbent assay (ELISA) of S100A8/A9, follistatin-like protein 1 and interleukin-18 (IL-18). Of the AOSD patients, follow-up samples were collected from 16 patients after resolution of disease activity. Furthermore, S100A8/A9 expression levels in biopsy specimens obtained from 26 AOSD patients with skin rashes and 8 AOSD with lymphadenopathy were investigated via immunohistochemistry. Peripheral blood mononuclear cells (PBMC) from active AOSD and HC were evaluated for IL-1β release, and in vitro study with PBMC and THP-1 cell line was done for cell signal of S100A8/A9. 



Results: Serum S100A8/A9 in AOSD patients was higher than those of RA patients and HC. However, follistatin-like protein 1 in AOSD was not different from RA and HC. The IL-18 levels of AOSD were higher than those of RA and HC. Serum S100A8/A9 correlated with leukocyte count, erythrocyte sedimentation rate, C-reactive protein (CRP), ferritin, and systemic score, however the IL-18 correlated only with ferritin and systemic score. In addition, S100A8/A9 was decreased after disease activity was resolved in followed-up AOSD patients. Furthermore, the IL-1β and TNF-α levels of AOSD were higher than those of HC. Serum S100A8/A9 levels correlated with IL-1β, TNF-α, ferritin, and CRP. The grade of inflammatory cells expressing S100A8/A9 ranged from 1 to 3 in skin and lymph node biopsies of active AOSD. The grading of staining of S100A8/A9 was more intense in inflammatory cells of skin lesions with karyrrhexis (p=0.028), mucin deposition (p=0.014), and neutrophil infiltration (p=0.006). Furthermore, the correlation between inflammatory cell grading of CD68 and that of S100A8/A9 was shown (p&lt;0.001) in skin biopsies. S100A9 was a strong inducer of IL-1β expression in peripheral blood mononuclear cells. S100A9 induced signal transduction pathways, including JNK and p38 in PBMC from HC and AOSD patients. 



Conclusion: The data suggest that serum S100A8/A9 may be a useful biomarker for evaluating disease activity in AOSD patients. Furthermore, S100A8/A9 may contribute to the inflammatory response by induction of inflammatory cytokines, and serve as a clinicopathological marker for assessment of disease activity in AOSD.</dc:description>
<dc:description>Ⅰ. INTRODUCTION 1 

Ⅱ. MATERIALS AND METHODS 4 

Ⅲ. RESULTS 9 

Ⅳ. DISCUSSION 34 

Ⅴ. CONCLUSION 39 

REFERENCES 40 

국문요약 48</dc:description>
<dc:description>Doctor</dc:description>
<dc:date>2015-11-03T04:16:15Z</dc:date>
<dc:date>2015-11-03T04:16:15Z</dc:date>
<dc:date>2015</dc:date>
<dc:date>2015</dc:date>
<dc:type>Thesis</dc:type>
<dc:type>Theses</dc:type>
<dc:identifier>http://repository.ajou.ac.kr/handle/201003/11887</dc:identifier>
<dc:identifier>http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000020404</dc:identifier>
<dc:identifier>000000020404</dc:identifier>
<dc:language>en</dc:language>
</oai_dc:dc>
</metadata></record></GetRecord></OAI-PMH>